These success, along with a preceding report displaying that a small-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like actions in mice,2 assist the thought of targeting ACKR3 as a novel technique to modulate the opioid procedure, which could open up new therapeutic avenues for opioid-releva